MedTrace Logo

Effect of Ziprasidone on Glucose & Plasma Lipids in Diabetes (II) and Schizophrenia or Schizoaffective Disorder

NCT00395031 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2011-07-29

No results posted yet for this study

Summary

The aim of the protocol is to study the effects of 320 mg/day of ziprasidone (Geodon) on glucose and lipid metabolism of patients with both Diabetes Type II (DM) and schizophrenia or schizoaffective disorder, after switching their antipsychotic medication/s from typical and/or atypical to ziprasidone monotherapy.

Conditions

Interventions

DRUG

Ziprasidone

Ziprasidone dose of between 40 mg po bid to 160 mg po bid for 8 weeks

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Manhattan Psychiatric Center

    lead OTHER

Principal Investigators

  • Saurabh Kaushik, M.D. · Manhattan Psychiatric Center, New York University, Nathan Kline Institute

  • Jean-Pierre Lindenmayer, M.D. · Manhattan Psychiatric Center, New York University, Nathan Kline Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00395031 on ClinicalTrials.gov